Detalhe da pesquisa
1.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
HIV Med
; 24(2): 202-211, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945163
2.
Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women.
Br J Clin Pharmacol
; 88(4): 1704-1712, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427938
3.
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33753329
4.
Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
Br J Clin Pharmacol
; 87(9): 3501-3507, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33533507
5.
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
N Engl J Med
; 369(19): 1807-18, 2013 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24195548
6.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Lancet
; 383(9936): 2222-31, 2014 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24698485
7.
Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.
Br J Clin Pharmacol
; 80(3): 502-14, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25819132
8.
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
J Infect Dis
; 210(3): 354-62, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24446523
9.
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
Clin Infect Dis
; 59(7): 1032-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24944232
10.
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Lancet
; 381(9868): 735-43, 2013 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23306000
11.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23830355
12.
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
J Infect Dis
; 207(5): 740-8, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23225901
13.
Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.
Antimicrob Agents Chemother
; 57(8): 3536-46, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23669385
14.
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
Open Forum Infect Dis
; 9(8): ofac304, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046700
15.
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
Antimicrob Agents Chemother
; 55(7): 3517-21, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21555764
16.
Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.
J Antimicrob Chemother
; 66(7): 1567-72, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21493648
17.
Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Br J Clin Pharmacol
; 72(1): 103-8, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21342217
18.
Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
Antimicrob Agents Chemother
; 54(1): 254-8, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19884365
19.
Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.
Am Heart J
; 159(5): 716-29, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20435178
20.
Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.
Pharmacol Res Perspect
; 8(6): e00671, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200887